Success Metrics

Clinical Success Rate
79.4%

Based on 108 completed trials

Completion Rate
79%(108/136)
Active Trials
11(5%)
Results Posted
28%(30 trials)
Terminated
28(13%)

Phase Distribution

Ph phase_1
29
14%
Ph not_applicable
22
11%
Ph phase_3
41
20%
Ph phase_2
105
50%
Ph phase_4
1
0%
Ph early_phase_1
2
1%

Phase Distribution

31

Early Stage

105

Mid Stage

42

Late Stage

Phase Distribution200 total trials
Early Phase 1First-in-human
2(1.0%)
Phase 1Safety & dosage
29(14.5%)
Phase 2Efficacy & side effects
105(52.5%)
Phase 3Large-scale testing
41(20.5%)
Phase 4Post-market surveillance
1(0.5%)
N/ANon-phased studies
22(11.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.5%

108 of 145 finished

Non-Completion Rate

25.5%

37 ended early

Currently Active

11

trials recruiting

Total Trials

208

all time

Status Distribution
Active(12)
Completed(108)
Terminated(37)
Other(51)

Detailed Status

Completed108
unknown50
Terminated28
Withdrawn9
Recruiting9
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
208
Active
11
Success Rate
79.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.0%)
Phase 129 (14.5%)
Phase 2105 (52.5%)
Phase 341 (20.5%)
Phase 41 (0.5%)
N/A22 (11.0%)

Trials by Status

suspended10%
not_yet_recruiting10%
unknown5024%
withdrawn94%
completed10852%
recruiting94%
active_not_recruiting21%
terminated2813%

Recent Activity

Clinical Trials (208)

Showing 20 of 208 trialsScroll for more
NCT00872625Phase 1

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Completed
NCT07103395Phase 2

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting
NCT07038122Not Applicable

Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers

Active Not Recruiting
NCT07089199Phase 2

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

Not Yet Recruiting
NCT06734702Phase 3

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Recruiting
NCT00354393Phase 2

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Completed
NCT00544414Phase 2

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Completed
NCT06792149

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

Recruiting
NCT06642428Not Applicable

Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer

Recruiting
NCT06385288Not Applicable

Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

Recruiting
NCT06630481

Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

Completed
NCT04085250Phase 2

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Active Not Recruiting
NCT00482755Phase 2

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed
NCT05173272Phase 3

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Recruiting
NCT06151379

Muscle Parameters and Pathological Response in Breast Cancer Patients

Completed
NCT06003673Phase 4

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

Unknown
NCT06080620Not Applicable

The Choice of Treatment Methods and Efficacy of LABC

Recruiting
NCT00499083Phase 2

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Completed
NCT00089024Phase 2

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed
NCT00665457Phase 2

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated

Drug Details

Intervention Type
PROCEDURE
Total Trials
208